Evolution :: Concord Biotech Limited

EVOLUTION

2021

Commenced operations at second API facility at Limbasi.
Third EU GMP inspection of our manufacturing facility located in Dholka.

2020

Board of the Company permitted the layout plan for the proposed injectable manufacturing unit at Valthera facility.
Received two ANDA approvals.
First shipment of Mycophenolate Sodium Tablets, in US market.

2019

Received two ANDA approvals.
Expansion of our company’s business in critical care segment in India.
Commencement of marketing of Mycophenolate Mofetil Capsules USP 250 mg.

2018

Fifth USFDA inspection and received ‘no action indicated’ classification for our facility located at Dholka.
Grant of GMP certification from Food and Drugs Control Administration for Valthera and Dholka units Second USFDA inspection at our facility located in Valthera facility and receipt of establishment inspection report.
Established Joint Venture in Japan pursuant to growing business opportunities in Japan.

2017

First USFDA inspection at our Valthera facility and receipt of establishment inspection report.

2016

Established a facility at Valthera, Gujarat.
Recognition of our in-house R&D facility located at Valthera by Ministry of Science and Technology, Government of India.
Investment from Helix

2015

Fourth USFDA inspection of our Dholka facility and conclusion of inspection as ‘closed’.
Second EU GMP inspection conducted in May 2014
Received accreditation certificate of foreign drug manufacturing for non-sterile drugs from Minister of Health, Labour and Welfare of Japan.

2014

Received certificate of drug substance registry for Ciclosporin JP from Pharmaceuticals and Medical Devices Agency, Japan.

2013

Third USFDA inspection and classification of our API facility as acceptable.

2012

Received original drug substance registration certificate for mycophenolate mofetil from Pharmaceuticals and Medical Devices Agency, Japan.

2011

First EU GMP inspection of our manufacturing facility by Government of Upper Bavaria- Central Medicines Control Bavaria (GMP/GCP).
Initiated CRAMs services in areas of new chemical entity (“NCE”) or Generic APIs.

2010

Received drug master file registration certificate for tacrolimus hydrate from Pharmaceuticals and Medical Devices Agency, Japan.

2008

Second USFDA inspection and classification of our API facility as acceptable.

2005

First USFDA inspection and classification of our API facility as acceptable.

2004

Investment by Rakesh Jhunjhunwala and Rekha Jhunjhunwala in our Company.

2003

Certification of our facility at Dholka for commissioning and commencement of production of various enzymes by technical consultants.

2002

Expansion of production capacity of enzymes

2001

Renaming of our Company to Concord Biotech Limited.

2000

Acquisition of our Company by Mr. Sudhir Vaid, one of our Promoters

THESE MATERIALS ARE NOT DIRECTED AT OR INTENDED TO BE ACCESSED BY PERSONS LOCATED OUTSIDE INDIA.

IMPORTANT: You must read and agree with the terms and conditions of the following disclaimer before continuing.

The following disclaimer applies to the Prospectus of Concord Biotech Limited(the “Company”) datedAugust 9, 2023(the “Prospectus”) filed with the Registrar of Companies, Gujarat at Ahmedabad and thereafter with theSecurities and Exchange Board of India (“SEBI”)and the BSE Limited and the National Stock Exchange of India Limited, in relation to the initial public offering of the equity shares of face value of ₹ 1 each (“Equity Shares”) of the Company (“Offer”).

THE PROSPECTUSIS BEING MADE AVAILABLE ON THIS WEBSITE TO COMPLY WITH SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED (“SEBI ICDR REGULATIONS”).In accessing the Prospectus, you agree to be bound by the following terms and conditions, including any modifications to them from time to time.

TheProspectus is directed at, and is intended for distribution to, and use by, residents of India only. The information in this portion of our website, including the Prospectus, is not for publication or distribution, directly or indirectly, in or into the United States. No part of the contents of the Prospectus shall be copied or duplicated in any form by any means, or redistributed.

The Prospectus has been hosted on this website as prescribed under Regulation 26 of the SEBI ICDR Regulations. You are reminded that documents transmitted in electronic form may be altered or changed during the process of transmission and consequently, neitherthe Companynor any of its affiliates accepts any liability or responsibility whatsoever in respect of alterations or changes which have taken place during the course of transmission of electronic data.

The Prospectus does not constitute an offer to sell or an invitation to subscribe to the securities offered in any jurisdiction to any person to whom it is unlawful to make an offer or invitation in such jurisdictionand is not intended for distribution to, or use by, any person or entity in any jurisdiction or countrywhere (a) distribution or use of such information would be contrary to law or regulation; or (b) the Companyor any of itsaffiliates would by virtue of such distribution become subject to new or additional registration, licensing or otherregulatory requirements. The Equity Shares offered in the Offer have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “U.S.Securities Act”) or any state securities laws in the United States, and unless so registered may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, such Equity Shares are being offered and sold (i) outside of the United States in “offshore transactions” as defined in and in compliance with Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sales occur; and (ii) to “qualified institutional buyers” (as defined in Rule 144A under the U.S. Securities Act) pursuant toSection 4(a) of the U.S. Securities Act.No person outside India is eligible to bid for Equity Shares in the Offer unless that person has received the preliminary offering memorandum for the Offer, which comprises the red herring prospectus dated July 27, 2023and the preliminary international wrap (which contains, among other things, the selling restrictions for the Offer outside India).

Any person into whose possession theProspectus comes is required to inform himself or herself about and to observe any such restrictions.

Neither the Company norany of its affiliates will be responsible for any loss or damage that could result from interception and interpretation by any third parties of any information being made available to you through this website. The Companyand its affiliates cannot and do not guarantee the accuracy, timeliness or completeness of the information being made available to you in the Prospectus beyond the date of the Prospectus. The information in the Prospectus is as of the date thereof and neither the Company nor its affiliates, directors or employees are under any obligation to update or revise the Prospectus to reflect circumstances arising after the date thereof.

Any potential investor should note that investment in equity shares involves a high degree of risk and for details relating to such risks, see the section titled “Risk Factors” of the Prospectus.

The Company and its affiliateswill not be responsible for any loss to any person or entity caused by any shortcoming, defect or inaccuracy which may have inadvertently or otherwise crept into the website. Neither the Company,any of its affiliates nor their directors, officers and employees will be liable or have any responsibility of any kind for any loss or damage that you incur in the event of any failure or disruption of this website, or resulting from the act or omission of any other party involved in making this website or the data contained therein available to you, or from any other cause relating to your access to, inability to access, or use of the website or these materials.

If you are not permitted to view the materials on this website or are in any doubt as to whether you are permitted to view these materials, please exit this webpage.

To access this information, you must confirm by pressing on the button marked "I Confirm" that, at the time of access you are located in India. If you cannot make this confirmation, you must press the button marked "I Do Not Confirm".

The documentation contained in these pages is posted solely to comply with Indian legal and regulatory requirements. Making the information contained herein available in electronic format does not constitute an offer to sell, the solicitation of an offer to buy, or a recommendation to buy or sell securities of the Company in the United States or in any other jurisdiction, including without limitation, India.

THESE MATERIALS ARE NOT DIRECTED AT OR INTENDED TO BE ACCESSED BY PERSONS LOCATED OUTSIDE INDIA.

IMPORTANT: You must read and agree with the terms and conditions of the following disclaimer before continuing.

The following disclaimer applies to the Red Herring Prospectus of Concord Biotech Limited(the “Company”) datedJuly 27, 2023(the “Red Herring Prospectus”) filed with the Registrar of Companies, Gujarat at Ahmedabad and thereafter with theSecurities and Exchange Board of India (“SEBI”)and the BSE Limited and the National Stock Exchange of India Limited, in relation to the initial public offering of the equity shares of face value of ₹ 1 each (“Equity Shares”) of the Company (“Offer”).

THE RED HERRING PROSPECTUSIS BEING MADE AVAILABLE ON THIS WEBSITE TO COMPLY WITH SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED (“SEBI ICDR REGULATIONS”).In accessing the Red Herring Prospectus, you agree to be bound by the following terms and conditions, including any modifications to them from time to time.

TheRed Herring Prospectus is directed at, and is intended for distribution to, and use by, residents of India only. The information in this portion of our website, including the Red Herring Prospectus, is not for publication or distribution, directly or indirectly, in or into the United States. No part of the contents of the Red Herring Prospectus shall be copied or duplicated in any form by any means, or redistributed.

The Red Herring Prospectus has been hosted on this website as prescribed under Regulation 26 of the SEBI ICDR Regulations. You are reminded that documents transmitted in electronic form may be altered or changed during the process of transmission and consequently, neitherthe Companynor any of its affiliates accepts any liability or responsibility whatsoever in respect of alterations or changes which have taken place during the course of transmission of electronic data.

The Red Herring Prospectus does not constitute an offer to sell or an invitation to subscribe to the securities offered in any jurisdiction to any person to whom it is unlawful to make an offer or invitation in such jurisdictionand is not intended for distribution to, or use by, any person or entity in any jurisdiction or countrywhere (a) distribution or use of such information would be contrary to law or regulation; or (b) the Companyor any of itsaffiliates would by virtue of such distribution become subject to new or additional registration, licensing or otherregulatory requirements. The Equity Shares offered in the Offer have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “U.S.Securities Act”) or any state securities laws in the United States, and unless so registered may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, such Equity Shares are being offered and sold (i) outside of the United States in “offshore transactions” as defined in and in compliance with Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sales occur; and (ii) to “qualified institutional buyers” (as defined in Rule 144A under the U.S. Securities Act) pursuant toSection 4(a) of the U.S. Securities Act.No person outside India is eligible to bid for Equity Shares in the Offer unless that person has received the preliminary offering memorandum for the Offer, which comprises the Red Herring Prospectus and the preliminary international wrap (which contains, among other things, the selling restrictions for the Offer outside India).

Any person into whose possession theRed Herring Prospectus comes is required to inform himself or herself about and to observe any such restrictions.

Neither the Company norany of its affiliates will be responsible for any loss or damage that could result from interception and interpretation by any third parties of any information being made available to you through this website. The Companyand its affiliates cannot and do not guarantee the accuracy, timeliness or completeness of the information being made available to you in the Red Herring Prospectus beyond the date of the Red Herring Prospectus. The information in the Red Herring Prospectus is as of the date thereof and neither the Company nor its affiliates, directors or employees are under any obligation to update or revise the Red Herring Prospectus to reflect circumstances arising after the date thereof.

Any potential investor should note that investment in equity shares involves a high degree of risk and for details relating to such risks, see the section titled “Risk Factors” on page 26 of the Red Herring Prospectus.

The Company and its affiliateswill not be responsible for any loss to any person or entity caused by any shortcoming, defect or inaccuracy which may have inadvertently or otherwise crept into the website. Neither the Company,any of its affiliates nor their directors, officers and employees will be liable or have any responsibility of any kind for any loss or damage that you incur in the event of any failure or disruption of this website, or resulting from the act or omission of any other party involved in making this website or the data contained therein available to you, or from any other cause relating to your access to, inability to access, or use of the website or these materials.

If you are not permitted to view the materials on this website or are in any doubt as to whether you are permitted to view these materials, please exit this webpage.

To access this information, you must confirm by pressing on the button marked "I Confirm" that, at the time of access you are located in India. If you cannot make this confirmation, you must press the button marked "I Do Not Confirm".

The documentation contained in these pages is posted solely to comply with Indian legal and regulatory requirements. Making the information contained herein available in electronic format does not constitute an offer to sell, the solicitation of an offer to buy, or a recommendation to buy or sell securities of the Company in the United States or in any other jurisdiction, including without limitation, India.